Table 1.
Patient characteristics at time of enrolment, split up according to the most common chemotherapy regimen
| F + A + C (n = 456) | F + A + C + D (n = 413) | A + C + P (n = 279) | A + C + D (n = 178) | All patients (N = 1650) | |
|---|---|---|---|---|---|
| Age at start of therapy (n)* | 456 | 413 | 278 | 178 | 1649 |
| Median (years) | 56.0 | 56.6 | 56.7 | 53.3 | 56.7 |
| BMI (n)* | 453 | 404 | 275 | 176 | 1626 |
| Mean (kg/m2) ± SD (kg/m2) | 26.8 ± 5.3 | 26.8 ± 5.3 | 26.5 ± 5.2 | 26.4 ± 4.9 | 26.8 ± 5.2 |
| n | % | n | % | n | % | n | % | n | % | |
|---|---|---|---|---|---|---|---|---|---|---|
| Any comorbiditya | 235 | 51.5 | 192 | 46.5 | 153 | 54.8 | 91 | 51.1 | 876 | 53.1 |
| CCI = 0 | 394 | 86.4 | 376 | 91.0 | 245 | 87.8 | 165 | 92.7 | 1443 | 87.5 |
| CCI = 1 | 29 | 6.4 | 13 | 3.1 | 15 | 5.4 | 4 | 2.2 | 71 | 4.3 |
| CCI ≥ 2 | 33 | 7.2 | 24 | 5.8 | 19 | 6.8 | 9 | 5 | 136 | 8.2 |
| Hypertension | 132 | 28.9 | 101 | 24.5 | 79 | 28.3 | 34 | 19.1 | 458 | 27.8 |
| Diabetes mellitus | 35 | 7.7 | 24 | 5.8 | 21 | 7.5 | 9 | 5.1 | 128 | 7.8 |
| Cardiovascular disorders | 6 | 1.3 | 3 | 0.7 | 5 | 1.8 | 1 | 0.6 | 39 | 2.4 |
| Tumour subtype (n)a | 442 | 403 | 275 | 175 | 1611 | |||||
| HR-positive/HER2-negative | 301 | 68.1 | 254 | 63.0 | 165 | 60.0 | 104 | 59.4 | 949 | 58.9 |
| HER2-positive | 83 | 18.8 | 87 | 21.6 | 61 | 22.2 | 29 | 16.6 | 402 | 25.0 |
| Triple negative | 58 | 13.1 | 62 | 15.4 | 49 | 17.8 | 42 | 24.0 | 260 | 16.1 |
| Tumour stagea,b | 403 | 364 | 248 | 162 | 1456 | |||||
| I | 197 | 48.9 | 59 | 16.2 | 33 | 13.3 | 31 | 19.1 | 407 | 28.0 |
| II | 194 | 48.1 | 245 | 67.3 | 115 | 46.4 | 80 | 49.4 | 763 | 52.4 |
| III | 12 | 3.0 | 60 | 16.5 | 100 | 40.3 | 51 | 31.5 | 286 | 19.6 |
| Nodal stagea | 456 | 413 | 279 | 178 | 1650 | |||||
| N− | 376 | 82.5 | 119 | 28.8 | 81 | 29.0 | 58 | 32.6 | 781 | 47.3 |
| N+ | 77 | 16.9 | 291 | 70.5 | 195 | 69.9 | 117 | 65.7 | 853 | 51.7 |
| NX | 3 | 0.7 | 3 | 0.7 | 3 | 1.1 | 3 | 1.7 | 16 | 1.0 |
| Local therapya | 456 | 413 | 279 | 178 | 1650 | |||||
| BCS | 362 | 79.4 | 296 | 71.7 | 173 | 62.0 | 120 | 67.4 | 1166 | 70.7 |
| Post-BCS radiotherapyc | 322 | 89.0 | 258 | 87.2 | 138 | 79.8 | 109 | 90.8 | 1001 | 85.8 |
| Mastectomy | 87 | 19.1 | 105 | 25.4 | 92 | 33.0 | 50 | 28.1 | 435 | 26.4 |
| Post-mastectomy radiotherapyd | 28 | 32.2 | 74 | 70.5 | 65 | 70.7 | 33 | 66.0 | 259 | 59.5 |
| Surgery unknown | 7 | 1.5 | 12 | 2.9 | 14 | 5.0 | 8 | 4.5 | 49 | 3.0 |
Only the four mainly used regimens are shown; each regimen could be administered with or without additional HER2-inhibitor trastuzumab and/or additional endocrine therapy
A epirubicin or doxorubicin, BCS breast conserving surgery, BMI body mass index, C cyclophosphamide, CCI Charlson comorbidity index, D docetaxel, Car carboplatin, F fluorouracil, P paclitaxel, SD standard deviation
aNumber of patients with data available on the respective parameter at time of enrolment
bTumour stage according to American Joint Committee on Cancer. 7th ed. New York, NY: Springer; 2010
cPercentages refer to all patients who received BCS
dPercentages refer to all patients who received mastectomy